FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213304969> ?p ?o ?g. }

• W4213304969 abstract "Abstract Background: Neoadjuvant chemotherapy (NAC) has been the standard treatment for locally advanced breast cancer for the purpose of downstaging or for conversion from mastectomy to breast conservation surgery (BCS). There is still a high locoregional recurrence (LRR) rate after NAC. The aim of this study was to determine predictive factors for locoregional recurrence (LRR) in breast cancer patients after NAC. Materials and Methods: Between 2005 and 2017, 1047 breast cancer patients underwent BCS or mastectomy after NAC in Chang Gung Memorial Hospital, Linkou. We obtained data regarding patient and tumor characteristics, chemotherapy regimens, clinical tumor response, tumor subtypes and pathological complete response (pCR), type of surgery, and recurrence. Results : The median follow-up time was 45.1 months (range 0.1-160.3 months). The mean initial tumor size was 4.89 cm (SD ±2.95 cm). Of the 1047 NAC patients, 232 (22.2%) achieved pCR. The BCS and mastectomy rates were 41% and 59%, respectively. Overall, 240 patients experienced tumor recurrence (22.9%). Thirty-five cases of LRR (14.3%) were noted following BCS, of which 4.3% achieved pCR. Multivariate analysis indicated that independent factors for the prediction of LRR included hormone receptor negative/human epidermal growth factor receptor 2 positive (HR-/HER2+) subtype, HR-/HER2- subtype, and failure to achieve pCR. Further investigation according to the molecular subtype showed that following BCS, HR-/HER2+ non-pCR group had significantly increased LRR compared with the HR+/HER2+ pCR group (22.2% vs 6.3%, p<0.05), and the HR-/HER2-non-pCR group had significantly increased LRR compared with the HR-/HER2-pCR group (0% vs 20.4%, p<0.005). Conclusion: Pathological response after NAC is related to the risk of developing LRR. The LRR rate was higher in non-pCR patients after NAC, especially in hormone receptor-negative patients undergoing BCS. Therefore, both the pathological response status and molecular subtype should be carefully considered when considering candidates for BCS after NAC." @default.
• W4213304969 created "2022-02-24" @default.
• W4213304969 creator A5009653018 @default.
• W4213304969 creator A5013543492 @default.
• W4213304969 creator A5015716810 @default.
• W4213304969 creator A5052192039 @default.
• W4213304969 creator A5058035186 @default.
• W4213304969 creator A5061020921 @default.
• W4213304969 creator A5064202379 @default.
• W4213304969 creator A5068252545 @default.
• W4213304969 creator A5077773534 @default.
• W4213304969 creator A5078888182 @default.
• W4213304969 date "2020-07-01" @default.
• W4213304969 modified "2023-09-26" @default.
• W4213304969 title "Higher Locoregional Recurrence in Hormone Receptor-Negative Breast Cancer Patients with Residual Disease after Neoadjuvant Treatment Undergoing Breast Conservation Surgery" @default.
• W4213304969 doi "https://doi.org/10.21203/rs.3.rs-37181/v1" @default.
• W4213304969 hasPublicationYear "2020" @default.
• W4213304969 type Work @default.
• W4213304969 citedByCount "0" @default.
• W4213304969 crossrefType "posted-content" @default.
• W4213304969 hasAuthorship W4213304969A5009653018 @default.
• W4213304969 hasAuthorship W4213304969A5013543492 @default.
• W4213304969 hasAuthorship W4213304969A5015716810 @default.
• W4213304969 hasAuthorship W4213304969A5052192039 @default.
• W4213304969 hasAuthorship W4213304969A5058035186 @default.
• W4213304969 hasAuthorship W4213304969A5061020921 @default.
• W4213304969 hasAuthorship W4213304969A5064202379 @default.
• W4213304969 hasAuthorship W4213304969A5068252545 @default.
• W4213304969 hasAuthorship W4213304969A5077773534 @default.
• W4213304969 hasAuthorship W4213304969A5078888182 @default.
• W4213304969 hasBestOaLocation W42133049691 @default.
• W4213304969 hasConcept C121608353 @default.
• W4213304969 hasConcept C126322002 @default.
• W4213304969 hasConcept C143998085 @default.
• W4213304969 hasConcept C207886595 @default.
• W4213304969 hasConcept C23589133 @default.
• W4213304969 hasConcept C2776694085 @default.
• W4213304969 hasConcept C2777757722 @default.
• W4213304969 hasConcept C2778292576 @default.
• W4213304969 hasConcept C2779786085 @default.
• W4213304969 hasConcept C2781467025 @default.
• W4213304969 hasConcept C530470458 @default.
• W4213304969 hasConcept C71924100 @default.
• W4213304969 hasConceptScore W4213304969C121608353 @default.
• W4213304969 hasConceptScore W4213304969C126322002 @default.
• W4213304969 hasConceptScore W4213304969C143998085 @default.
• W4213304969 hasConceptScore W4213304969C207886595 @default.
• W4213304969 hasConceptScore W4213304969C23589133 @default.
• W4213304969 hasConceptScore W4213304969C2776694085 @default.
• W4213304969 hasConceptScore W4213304969C2777757722 @default.
• W4213304969 hasConceptScore W4213304969C2778292576 @default.
• W4213304969 hasConceptScore W4213304969C2779786085 @default.
• W4213304969 hasConceptScore W4213304969C2781467025 @default.
• W4213304969 hasConceptScore W4213304969C530470458 @default.
• W4213304969 hasConceptScore W4213304969C71924100 @default.
• W4213304969 hasLocation W42133049691 @default.
• W4213304969 hasLocation W42133049692 @default.
• W4213304969 hasOpenAccess W4213304969 @default.
• W4213304969 hasPrimaryLocation W42133049691 @default.
• W4213304969 hasRelatedWork W1255356622 @default.
• W4213304969 hasRelatedWork W1970677298 @default.
• W4213304969 hasRelatedWork W1991307975 @default.
• W4213304969 hasRelatedWork W2161568138 @default.
• W4213304969 hasRelatedWork W2335827814 @default.
• W4213304969 hasRelatedWork W2381572134 @default.
• W4213304969 hasRelatedWork W2413019411 @default.
• W4213304969 hasRelatedWork W3092162558 @default.
• W4213304969 hasRelatedWork W4313643902 @default.
• W4213304969 hasRelatedWork W4322775462 @default.
• W4213304969 isParatext "false" @default.
• W4213304969 isRetracted "false" @default.
• W4213304969 workType "article" @default.